Back to catalogue
№ 204 32 filings · 2021-11-17 → 2026-09-30

FEVARA PLC

FVA
Food, Beverage and Tobacco Share price 158p Market cap £82m Overall fit 220 /1000

Fairly priced, well-run specialty animal-nutrition business with a fortress balance sheet — but essentially zero AI-receiver exposure and only moderate operating leverage, making it a poor fit for a strategy anchored on direct AI-spending beneficiaries with high operating gearing.

Fair value range 130p–170p Mid case · £78m
Absolute upside -4.7% vs current market cap
Conviction 4/5 confidence in fair call
Supports the call
  • FY26 EBIT already pre-announced in Sept trading update
  • clean net-cash balance sheet with transparent disclosure
  • two valuation approaches converge on 140–170p
Limits the call
  • medium-term £120m revenue target depends on unproven Brazil execution
  • weather/cycle sensitivity creates near-term earnings volatility
Methodology

Blended forward P/E (15–20x) and EV/EBITDA (9–11x) cross-checked against discounted medium-term ambition

In one line · bull case

A newly-focused, clean-balance-sheet specialty livestock-supplements business with a credible path to doubling EBIT over 3–5 years via Brazil, available at a fair price.

In one line · biggest risk

The medium-term growth ambition depends on successful rollout of UK/EU-style low-moisture-block products in Brazil, an unproven market for Fevara.

Drivers
AI beneficiary 5 /100
Livestock supplements business with no identifiable AI revenue line, AI-expanded addressable market, or AI productivity moat.
Operating leverage 45 /100
Moderate: 22% H1 FY26 EBIT growth on flat revenue reflects fixed-cost reduction and mix, but raw-material-heavy cost base limits pure leverage.
Earnings vs expectations 65 /100
Pattern has moved from historical misses (FY22–23 audit/trading issues) through in-line (FY25) to a clear beat vs consensus in FY26.
Growth momentum 70 /100
Accelerating: FY26 revenue +8% LFL, adjusted EBIT +60% YoY; Brazilian expansion provides optionality.
Moat 45 /100
Narrow but real: established brands (Crystalyx, Horslyx, Tracesure), patented production processes, 40+ documented university trials, established distribution.
Earnings quality 60 /100
Elevated adjusting items during restructuring (M&A, pension buy-in, restructuring) but transitional; cash conversion 112% of adjusted EBITDA in FY25.
Management quality 65 /100
New team under Hoopes delivering disposals, cost cuts and credible Brazil entry; beat FY26 consensus; AGM dissent on one NED a minor flag.
Cyclicality 50 /100
Moderate — exposed to beef herd cycles, livestock prices and weather (H1 FY26 US north hit by warmest winter in 132 years).
Leverage 12 /100
Net debt £2m vs £8m+ EBITDA = <0.3x; £20m committed RCF to Nov 2028; targeted leverage <1x. Fortress.

FEVARA PLC (FVA) — Investment Research Note

Executive summary

Fevara plc is a UK-listed international specialist in livestock supplements — manufacturing feed licks, low moisture blocks (LMB), bagged minerals and boluses for cattle, sheep and horses under brands including Crystalyx®, Horslyx®, Scotmin and Tracesure®, with manufacturing in the UK, US and (new) Brazil. The last two years mark a transformation: the former Carr's Group has divested its Engineering Division (£75m enterprise value, April 2025), returned £70m to shareholders via a tender offer (June 2025), rebranded as Fevara (October 2025), and acquired Macal and Cia do Sal to establish a Brazilian platform — with FY26 adjusted EBIT guided c.£6.0m, up ~60% year-on-year and ahead of consensus. The single most important point for valuation today: the stock is a reasonably priced, clean-balance-sheet, newly-focused specialty animal-nutrition business — but one with essentially zero relevance to AI-receiver investing.

Fair value estimate

Fair value range: 130p – 170p per share, implying £67m–£88m market cap (midpoint £150p / £78m).

Methodology — blended:

  • Multiple on near-term earnings. FY26 guided adjusted EBIT £6.0m; after net interest ~£0.3m and 24.5% tax ≈ £4.3m attributable PAT ≈ 8.3p EPS. At 15–20x (reasonable for a cash-generative branded specialty consumer-staples business of this scale), that gives 125p–165p. 2026-09-30 trading update; 2026-04-22 interim results
  • EV/EBITDA cross-check. FY26 adjusted EBITDA ~£7m from continuing ops, plus £1.6m JV contribution ≈ £8.6m. At 9–11x EV/EBITDA = EV £77m–£95m; minus £2m net debt = £75m–£93m equity, or 145p–180p.
  • Discounted medium-term ambition. Management's stated 3–5-year target of £120m revenue / £15m adjusted EBITDA / 10% EBIT margin / 20% ROCE 2026-04-22 interim implies ~£12m EBIT. At 10x and discounted 3 years at 10% ≈ 180p — delivers upside if ambition is met, but requires successful Brazilian scale-up.

Compared to current market cap of £74.8m (144.5p): the shares sit near the midpoint of our fair-value range. Absolute upside/downside: ~+4% to midpoint; range of –10% to +18%. View: fair.

Sector context

Classification confirmed: Consumer Staples / Food, Beverage and Tobacco (ICB). The business is best described as specialty animal nutrition — a niche within agricultural inputs. Fevara's quality profile (branded, patented, R&D-backed, cash-generative, net-cash balance sheet) is above typical small-cap consumer staples peers; its growth profile is above (post-restructuring); its leverage is well below sector norm (net cash). Listed peer comparables: Anpario plc (ANP) — closest direct peer, UK-listed specialty animal nutrition; Devenish / Treatt (TET) as adjacent flavour/specialty branded consumables; and larger comparables DSM-Firmenich / Alltech (private) for scale read-across.

Investment thesis (3 bullets)

  • Transformational refocusing is now largely complete and visibly improving profitability. Adjusted EBIT grew from £2.2m (FY24) → £3.7m (FY25) → ~£6.0m guided (FY26), on broadly flat revenue, driven by exit of loss-makers (Afgritech, Silver Springs, Animax, New Zealand sub-scale ops), a 27% H1 reduction in central costs, and improving UK/Europe owned-op margins (26% H1 FY26 EBIT growth). 2026-04-22 interim; 2026-09-30 trading update
  • Brazilian entry is a credible long-tail growth optionality. Brazil has >200m head of cattle — more than all of Fevara's existing Northern Hemisphere markets combined — and Macal + Cia do Sal provide ~86m head of addressable catchment, with LMB production launch targeted Q4 FY27. Management describes it as "the US market 20–30 years ago". 2025-12-03 acquisition; 2026-03-18 Brazil acquisition
  • Fortress balance sheet and progressive dividend policy at modest valuation. Net debt of £2.0m vs £15m EBITDA target implies <0.2x leverage even today; £20m committed + £10m uncommitted RCF with HSBC to Nov 2028; dividend cover target 2x; sector-typical quality at ~12.5x forward EBIT. 2026-09-30; 2025-12-10 full-year

Key risks (3 bullets)

  • Weather and herd-cycle sensitivity remains structural. H1 FY26 US northern-states volumes fell 11% on the second-warmest winter in 132 years, offsetting 28% southern-state growth. 2026-04-22 interim US beef herd cycle is only at suspected bottom — material herd rebuild is a 2–3 year wait.
  • Brazil execution risk. Two new acquisitions totalling £9.3m consideration, a £4m LMB installation ahead, deferred/contingent consideration up to £1.9m, operating in a new regulatory, currency and competitive environment. The LMB-in-Brazil thesis is unproven — "early trading in line with management expectations" is thin evidence. 2026-04-22 interim
  • Governance signal from AGM 2026. Resolution 6 (re-election of NED Gillian Watson) attracted 39.26% votes against — the Board's own explanation (missed meetings) is modest; shareholder dissent at this scale is a yellow flag worth monitoring. 2026-07-23 AGM update

Operating leverage

Fevara is a moderately operationally geared business, not a software-like leverage story. Cost of sales ran at 71.7% of revenue in H1 FY26 (vs 77.3% in H1 FY25), reflecting improving gross margin as mix shifts to higher-margin LMB and minerals. Gross margin was 28.3% in H1 FY26 vs 22.6% in H1 FY25. Central costs were cut 27% in H1 FY26, a real fixed-cost reduction that drops through directly. The clearest observable operating leverage: H1 FY26 adjusted operating profit rose 22% on flat revenue (£50.6m both halves) 2026-04-22 interim — but this includes JV contribution and favourable mix. Capacity utilisation at Belle Fourche (South Dakota) is strong; Oklahoma restructuring unlocked 28% H1 FY26 southern-state volume growth, implying meaningful spare capacity to absorb incremental orders. Estimate: a 10–20% revenue upside above current plan — e.g. revenue reaching £100m — could plausibly add ~£4m–£6m to adjusted EBIT (i.e. roughly doubling it to £10–12m), as the fixed-cost base is now right-sized. This is credible but modest versus pure-software leverage; raw-material (molasses, minerals) remains a large variable cost.

Value-trap signals

None material identified. Positive on: clean balance sheet; recent material disposal realised at reasonable value; new management team; progressive dividend policy with 2x cover; no going-concern concerns. Mild amber flags: 39% AGM dissent on one NED; pension buy-in process still ongoing (£3.4m escrow); goodwill of £6.7m is small relative to equity; adjusting items of £1.3m in H1 FY26 (M&A costs, pension buy-in costs) are elevated but transitional and consistent with the strategic reset.

Earnings vs. expectations

Over the covered period, the pattern improved from miss-prone to beat-prone:

  • FY22–FY23: The old Carr's Group suspended trading in Jan 2023 due to audit delays, missed audit deadlines, and underlying Agriculture performance was weaker than hoped. 2023-01-04 suspension; 2023-02-21 trading update
  • FY24: Full-year adjusted operating profit from continuing operations £2.2m — described as "ahead of market expectations" at the Oct 2024 trading update 2024-10-09 but on a reset basis.
  • FY25: Adjusted EBIT £3.7m. Trading update Sept 2025 flagged consensus as revenue £80m / adj OP £3.6m; actual revenue £78.8m, EBIT £3.7m — essentially in-line to small beat on profit. 2025-09-23
  • FY26 (guided): Adjusted EBIT ~£6.0m vs analyst consensus £5.5m at 29 Sept 2026 — a clear beat. 2026-09-30 trading update

Pattern: moving from historical misses and audit-driven credibility damage (through FY22–FY23) to in-line (FY25) to a credible beat (FY26). Two clean sets of results support a cautiously improving earnings-surprise trend.

Conviction

Conviction: 4 — high.

Anchors: (i) FY26 revenue and EBIT numbers were pre-announced in the September trading update 2026-09-30 — very little guesswork on near-term earnings; (ii) net debt is small and transparently stated at ~£2m; (iii) the business model is a mature, slow-moving branded consumer-staples specialty that is unlikely to see sudden margin shocks; (iv) two different valuation methods (P/E and EV/EBITDA) converge near 140–170p.

Caveats: (i) The medium-term ambition (£120m revenue, 10% EBIT margin) is management-set and depends heavily on Brazil execution over the next 3–5 years — if that scenario doesn't materialise, fair value drifts to the lower end; (ii) the business is weather- and cycle-sensitive, so near-term earnings volatility is higher than a "quality compounder" valuation would normally tolerate.

Driver scoring and overall score

This is a clean, well-run specialty consumer-staples business trading at a fair price with a sound balance sheet. For this investor's AI-receiver + operating-leverage strategy, it is a poor fit. No credible AI-receiver story; moderate (not high) operating leverage; valuation is fair but requires no "AI bull case" to justify. Downside protection is strong. Overall this is a low-fit stock for the strategy — the sort of name worth knowing exists but not pursuing.

Filings consulted · 48

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-09-30Trading Update2026-09-30_9797660_trading-update.md0.85
  2. 2026-08-11Chirton Disposal Amp Completion OF Strategic Refocus2026-08-11_9716142_chirton-disposal-amp-completion-of-strategic-refocus.md0.75
  3. 2026-07-23Result OF Agm Update Statement2026-07-23_9685007_result-of-agm-update-statement.md0.30
  4. 2026-04-22Interim Results2026-04-22_9531505_interim-results.md0.90
  5. 2026-04-13Notice OF Investor Presentation2026-04-13_9515864_notice-of-investor-presentation.md0.70
  6. 2026-04-02Notice OF Interim Results2026-04-02_9504573_notice-of-interim-results.md0.77
  7. 2026-03-18Strategic Acquisition IN Brazil2026-03-18_9479233_strategic-acquisition-in-brazil.md0.64
  8. 2026-02-12Result OF Agm2026-02-12_9426811_result-of-agm.md0.26
  9. 2025-12-24Completion OF Acquisition2025-12-24_9316796_completion-of-acquisition.md0.64
  10. 2025-12-19Notice OF Agm And Publication OF Annual Report2025-12-19_9309818_notice-of-agm-and-publication-of-annual-report.md0.81
  11. 2025-12-10Full Year Results2025-12-10_9286451_full-year-results.md0.85
  12. 2025-12-03Acquisition OF Domino Industria E Comercio Ltda2025-12-03_9271811_acquisition-of-domino-industria-e-comercio-ltda.md0.64
  13. 2025-11-28Notice OF Results And Investor Presentation2025-11-28_9262700_notice-of-results-and-investor-presentation.md0.59
  14. 2025-09-25Change OF Name2025-09-25_9132586_change-of-name.md0.39
  15. 2025-09-23Trading Update And Name Change2025-09-23_9124476_trading-update-and-name-change.md0.55
  16. 2025-05-07Interim Results And Ceo Succession2025-05-07_8864033_interim-results-and-ceo-succession.md0.58
  17. 2025-02-14Result OF Agm2025-02-14_8738104_result-of-agm.md0.20
  18. 2024-12-24Notice OF Agm And Publication OF Ara For Fy242024-12-24_8629230_notice-of-agm-and-publication-of-ara-for-fy24.md0.20
  19. 2024-12-12Full Year Results2024-12-12_8605793_full-year-results.md0.65
  20. 2024-10-09Trading Update2024-10-09_8474184_trading-update.md0.55
  21. 2024-04-24Replacement Strategic Update And Interim Results2024-04-24_8154453_replacement-strategic-update-and-interim-results.md0.43
  22. 2024-04-18Strategic Update And Interim Results2024-04-18_8143579_strategic-update-and-interim-results.md0.43
  23. 2024-01-10Notice OF Agm 2024 And 2023 Annual Report2024-01-10_7984161_notice-of-agm-2024-and-2023-annual-report.md0.43
  24. 2023-12-27Publication OF Annual Report And Accounts 20232023-12-27_7963297_publication-of-annual-report-and-accounts-2023.md0.43
  25. 2023-12-21Full Year Results2023-12-21_7955324_full-year-results.md0.45
  26. 2023-10-10Trading Update2023-10-10_7806288_trading-update.md0.38
  27. 2023-08-04Trading Update2023-08-04_7675678_trading-update.md0.21
  28. 2023-05-02Interim Results2023-05-02_7507431_interim-results.md0.23
  29. 2023-04-27Notice OF Interim Results2023-04-27_5935_notice-of-interim-results.md0.23
  30. 2023-04-06Notice OF GM Amp Circulation OF Annual Report 20222023-04-06_7459394_notice-of-gm-amp-circulation-of-annual-report-2022.md0.24
  31. 2023-03-29Restoration OF Trading2023-03-29_7376518_restoration-of-trading.md0.15
  32. 2023-03-23Publication OF Annual Report And Accounts 20222023-03-23_7279026_publication-of-annual-report-and-accounts-2022.md0.24
  33. 2023-03-23Full Year Results2023-03-23_7278356_full-year-results.md0.25
  34. 2023-03-21Update ON Publication OF Full Year Results2023-03-21_7276242_update-on-publication-of-full-year-results.md0.25
  35. 2023-02-28Result OF Agm 20232023-02-28_7238758_result-of-agm-2023.md0.07
  36. 2023-02-21Full Year Trading Update Unaudited2023-02-21_7501422_full-year-trading-update-unaudited.md0.21
  37. 2023-02-10Audit Timing And Trading Update2023-02-10_7449468_audit-timing-and-trading-update.md0.21
  38. 2023-01-04Update ON Audit And Temporary Suspension OF Shares2023-01-04_7309089_update-on-audit-and-temporary-suspension-of-shares.md0.25
  39. 2022-11-22Trading Update And Delay TO Audited Results2022-11-22_7454095_trading-update-and-delay-to-audited-results.md0.21
  40. 2022-10-26Agricultural Supplies Division Disposal Complete2022-10-26_7160133_agricultural-supplies-division-disposal-complete.md0.19
  41. 2022-08-31Disposal OF Interests IN Agricultural Supplies2022-08-31_7107685_disposal-of-interests-in-agricultural-supplies.md0.19
  42. 2022-08-05Trading Update2022-08-05_7010572_trading-update.md0.21
  43. 2022-04-20Half Year Report2022-04-20_6986045_half-year-report.md0.23
  44. 2022-01-18Trading Update2022-01-18_6906193_trading-update.md0.21
  45. 2022-01-18Result OF Agm2022-01-18_6907543_result-of-agm.md0.07
  46. 2021-12-15Notice OF Agm2021-12-15_6833186_notice-of-agm.md0.07
  47. 2021-12-07Full Year Results2021-12-07_6754286_full-year-results.md0.25
  48. 2021-11-17Fy21 Full Year Results Revised Date2021-11-17_6789959_fy21-full-year-results-revised-date.md0.25

This research note was authored by a large language model after reading 32 regulatory filings published between 2021-11-17 and 2026-09-30. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.